Adoptive transfer of virus-specific and tumor-specific T cell immunity

Current Opinion in Immunology

Volumn 21, Issue 2, 2009, Pages 224-232

  Berger, Carolina ^a   Turtle, Cameron J ^a   Jensen, Michael C ^b   Riddell, Stanley R ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CHIMERIC ANTIGEN RECEPTOR; CHIMERIC PROTEIN; GLUCOCORTICOID; INTERLEUKIN 15; INTERLEUKIN 7; LYMPHOCYTE ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN SPECIFICITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FATE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS; GENETIC ENGINEERING; HERPES VIRUS INFECTION; HUMAN; MELANOMA; NONHUMAN; OPPORTUNISTIC INFECTION; PERSISTENT VIRUS INFECTION; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE RECEPTOR GENE; T LYMPHOCYTE SUBPOPULATION; VIRUS INFECTION; VIRUS REACTIVATION;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, NEOPLASM; HUMANS; MODELS, IMMUNOLOGICAL; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; VIRUS DISEASES;

EID: 65249128775     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2009.02.010     Document Type: Review

References (62)

1. Dunn G.P., Old L.J., and Schreiber R.D. The three Es of cancer immunoediting. Annu Rev Immunol 22 (2004) 329-360
2. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., Tosolini M., Camus M., Berger A., Wind P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006) 1960-1964
3. Cobbold M., Khan N., Pourgheysari B., Tauro S., McDonald D., Osman H., Assenmacher M., Billingham L., Steward C., Crawley C., et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 202 (2005) 379-386
4. Rooney C.M., Smith C.A., Ng C.Y., Loftin S.K., Sixbey J.W., Gan Y., Srivastava D.K., Bowman L.C., Krance R.A., Brenner M.K., et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92 (1998) 1549-1555
5. Walter E.A., Greenberg P.D., Gilbert M.J., Finch R.J., Watanabe K.S., Thomas E.D., and Riddell S.R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333 (1995) 1038-1044
6. Dudley M.E., Wunderlich J., Nishimura M.I., Yu D., Yang J.C., Topalian S.L., Schwartzentruber D.J., Hwu P., Marincola F.M., Sherry R., et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 24 (2001) 363-373
7. Gattinoni L., Powell Jr. D.J., Rosenberg S.A., and Restifo N.P. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 6 (2006) 383-393
8. Mackensen A., Meidenbauer N., Vogl S., Laumer M., Berger J., and Andreesen R. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 24 (2006) 5060-5069
9. Yee C., Thompson J.A., Byrd D., Riddell S.R., Roche P., Celis E., and Greenberg P.D. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 99 (2002) 16168-16173
10. Appelbaum F.R. The current status of hematopoietic cell transplantation. Annu Rev Med 54 (2003) 491-512
11. Boeckh M., Leisenring W., Riddell S.R., Bowden R.A., Huang M.L., Myerson D., Stevens-Ayers T., Flowers M.E., Cunningham T., and Corey L. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101 (2003) 407-414
12. Einsele H., Roosnek E., Rufer N., Sinzger C., Riegler S., Loffler J., Grigoleit U., Moris A., Rammensee H.G., Kanz L., et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99 (2002) 3916-3922
13. Peggs K.S., Verfuerth S., Pizzey A., Khan N., Guiver M., Moss P.A., and Mackinnon S. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 362 (2003) 1375-1377
14. Becker C., Pohla H., Frankenberger B., Schuler T., Assenmacher M., Schendel D.J., and Blankenstein T. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat Med 7 (2001) 1159-1162
15. Knabel M., Franz T.J., Schiemann M., Wulf A., Villmow B., Schmidt B., Bernhard H., Wagner H., and Busch D.H. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat Med 8 (2002) 631-637
16. Hahn T., McCarthy Jr. P.L., Zhang M.J., Wang D., Arora M., Frangoul H., Gale R.P., Hale G.A., Horan J., Isola L., et al. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol 26 (2008) 5728-5734
17. Ashwell J.D., Lu F.W., and Vacchio M.S. Glucocorticoids in T cell development and function. Annu Rev Immunol 18 (2000) 309-345
18. Franchimont D. Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann N Y Acad Sci 1024 (2004) 124-137
19. Lowenberg M., Verhaar A.P., van den Brink G.R., and Hommes D.W. Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression. Trends Mol Med 13 (2007) 158-163
20. Durai S., Mani M., Kandavelou K., Wu J., Porteus M.H., and Chandrasegaran S. Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells. Nucleic Acids Res 33 (2005) 5978-5990
21. Gottschalk S., Heslop H.E., and Rooney C.M. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma 46 (2005) 1-10
22. Haque T., Wilkie G.M., Jones M.M., Higgins C.D., Urquhart G., Wingate P., Burns D., McAulay K., Turner M., Bellamy C., et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110 (2007) 1123-1131. This study reports the results of infusing allogeneic EBV-specific T cells derived from HLA partially matched unrelated donors to 33 patients with EBV post-transplant lymphoproliferative disorder. The T cell infusions were well tolerated and the overall response rate was 64% at 5 weeks and 52% at 6 months, demonstrating that allogeneic T cells can persist and mediate an antitumor effect in these highly immunocompromised patients.
23. Bollard C.M., Gottschalk S., Leen A.M., Weiss H., Straathof K.C., Carrum G., Khalil M., Wu M.F., Huls M.H., Chang C.C., et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110 (2007) 2838-2845
24. Louis CU, Straathof K, Bollard CM, Gerken C, Huls MH, Gresik MV, Wu MF, Weiss HL, Gee AP, Brenner MK et al.: Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood 2008, Oct. 29 [Epub ahead of print].
25. Boeckh M. The challenge of respiratory virus infections in hematopoietic cell transplant recipients. Br J Haematol 143 (2008) 455-467
26. Wong A.S., Cheng V.C., Yuen K.Y., Kwong Y.L., and Leung A.Y. High frequency of polyoma BK virus shedding in the gastrointestinal tract after hematopoietic stem cell transplantation: a prospective and quantitative analysis. Bone Marrow Transplant 43 (2009) 43-47
27. Leen A.M., Myers G.D., Sili U., Huls M.H., Weiss H., Leung K.S., Carrum G., Krance R.A., Chang C.C., Molldrem J.J., et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 12 (2006) 1160-1166. This study describes a cell culture system that can be used to simultaneously elicit T cells specific for cytomegalovirus, Epstein Barr virus, and adenovirus for adoptive immunotherapy of immunodeficient stem cell transplant recipients. The approach is based on the infection of donor EBV transformed B lymphocytes with a replication defective adenovirus that encoded the immunodominant cytomegalovirus pp65 protein and the use of these B cells as antigen presenting cells. The adoptive transfer of T cells elicited by this approach augmented T cell immunity to all three viruses and mediated antiviral activity.
28. Brodie S.J., Lewinsohn D.A., Patterson B.K., Jiyamapa D., Krieger J., Corey L., Greenberg P.D., and Riddell S.R. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med 5 (1999) 34-41
29. Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., Mackey E.W., Miller J.D., Leslie A.J., DePierres C., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443 (2006) 350-354
30. Jones R.B., Ndhlovu L.C., Barbour J.D., Sheth P.M., Jha A.R., Long B.R., Wong J.C., Satkunarajah M., Schweneker M., Chapman J.M., et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 205 (2008) 2763-2779
31. Urbani S., Amadei B., Tola D., Massari M., Schivazappa S., Missale G., and Ferrari C. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol 80 (2006) 11398-11403
32. Joseph A., Zheng J.H., Follenzi A., Dilorenzo T., Sango K., Hyman J., Chen K., Piechocka-Trocha A., Brander C., Hooijberg E., et al. Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity. J Virol 82 (2008) 3078-3089
33. Varela-Rohena A., Molloy P.E., Dunn S.M., Li Y., Suhoski M.M., Carroll R.G., Milicic A., Mahon T., Sutton D.H., Laugel B., et al. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med 14 (2008) 1390-1395
34. + memory T cell pool in HIV infection by adoptive transfer of CCR-5 gene edited T cells.
35. Drake C.G., Jaffee E., and Pardoll D.M. Mechanisms of immune evasion by tumors. Adv Immunol 90 (2006) 51-81
36. Kaiser B.K., Yim D., Chow I.T., Gonzalez S., Dai Z., Mann H.H., Strong R.K., Groh V., and Spies T. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 447 (2007) 482-486
37. Thomas D.A., and Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8 (2005) 369-380
38. Vence L., Palucka A.K., Fay J.W., Ito T., Liu Y.J., Banchereau J., and Ueno H. Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc Natl Acad Sci U S A 104 (2007) 20884-20889
39. Colombo M.P., and Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 7 (2007) 880-887
40. Tan J.T., Dudl E., LeRoy E., Murray R., Sprent J., Weinberg K.I., and Surh C.D. IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc Natl Acad Sci U S A 98 (2001) 8732-8737
41. Tan J.T., Ernst B., Kieper W.C., LeRoy E., Sprent J., and Surh C.D. Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J Exp Med 195 (2002) 1523-1532
42. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 (2002) 850-854
43. Dudley M.E., Wunderlich J.R., Yang J.C., Sherry R.M., Topalian S.L., Restifo N.P., Royal R.E., Kammula U., White D.E., Mavroukakis S.A., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23 (2005) 2346-2357
44. Dudley M.E., Yang J.C., Sherry R., Hughes M.S., Royal R., Kammula U., Robbins P.F., Huang J., Citrin D.E., Leitman S.F., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26 (2008) 5233-5239. This study updates the results of adoptive T cell therapy for patients with advanced melanoma with in vitro expanded autologous tumor infiltrating lymphocytes that were administered after various lymphodepleting regimens that increase the circulating levels of interleukin 7 and interleukin 15. The results in 93 patients show an objective response rate of 56%, which is superior to the historical experience when tumor infiltrating lymphocytes were administered without lymphodepleting chemotherapy.
45. Robbins P.F., Dudley M.E., Wunderlich J., El-Gamil M., Li Y.F., Zhou J., Huang J., Powell Jr. D.J., and Rosenberg S.A. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 173 (2004) 7125-7130
46. Wrzesinski C., Paulos C.M., Gattinoni L., Palmer D.C., Kaiser A., Yu Z., Rosenberg S.A., and Restifo N.P. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J Clin Invest 117 (2007) 492-501
47. + T cells in adoptive T cell therapy of human malignancies.
48. Sallusto F., Geginat J., and Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22 (2004) 745-763
49. Wherry E.J., Teichgraber V., Becker T.C., Masopust D., Kaech S.M., Antia R., von Andrian U.H., and Ahmed R. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 4 (2003) 225-234
50. Chang J.T., Palanivel V.R., Kinjyo I., Schambach F., Intlekofer A.M., Banerjee A., Longworth S.A., Vinup K.E., Mrass P., Oliaro J., et al. Asymmetric T lymphocyte division in the initiation of adaptive immune responses. Science 315 (2007) 1687-1691. This study provides evidence that asymmetric cell division during the activation of a naïve T cell may in part explain the distinct fates that are adopted by T cells during an immune response. The model presented demonstrates the unequal partitioning of fate determining proteins to daughter cells that determines their differentiation into effector or central memory T cells.
51. Zhang Y., Joe G., Hexner E., Zhu J., and Emerson S.G. Host-reactive CD8+ memory stem cells in graft-versus-host disease. Nat Med 11 (2005) 1299-1305
52. Ho W.Y., Nguyen H.N., Wolfl M., Kuball J., and Greenberg P.D. In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naive repertoire. J Immunol Methods 310 (2006) 40-52
53. Berger C., Jensen M.C., Lansdorp P.M., Gough M., Elliott C., and Riddell S.R. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 118 (2008) 294-305. This study uses gene marking to track the fate of clonally derived effector T cells isolated from either central memory or effector memory precursors in a non human primate model. Remarkably, effector cells derived from central memory but not effector memory precursors retained the capacity to persist long-term, reacquire a memory phenotype and replenish both central memory and effector memory pools. These results are consistent with the effector memory pool being replenished from central memory T cells, and suggest that deriving effector cells for adoptive therapy from central memory precursors will provide a cell population with greater intrinsic capacity to persist in vivo.
54. Hinrichs C.S., Spolski R., Paulos C.M., Gattinoni L., Kerstann K.W., Palmer D.C., Klebanoff C.A., Rosenberg S.A., Leonard W.J., and Restifo N.P. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 111 (2008) 5326-5333
55. Klebanoff C.A., Gattinoni L., Torabi-Parizi P., Kerstann K., Cardones A.R., Finkelstein S.E., Palmer D.C., Antony P.A., Hwang S.T., Rosenberg S.A., et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A 102 (2005) 9571-9576
56. Segal N.H., Parsons D.W., Peggs K.S., Velculescu V., Kinzler K.W., Vogelstein B., and Allison J.P. Epitope landscape in breast and colorectal cancer. Cancer Res 68 (2008) 889-892
57. Wood L.D., Parsons D.W., Jones S., Lin J., Sjoblom T., Leary R.J., Shen D., Boca S.M., Barber T., Ptak J., et al. The genomic landscapes of human breast and colorectal cancers. Science 318 (2007) 1108-1113
58. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., Royal R.E., Topalian S.L., Kammula U.S., Restifo N.P., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 (2006) 126-129. This is the first study in which autologous T cells were genetically altered to express a tumor-reactive T cell receptor by retrovirus mediated gene transfer and adoptively transferred to treat melanoma. A small number of patients had tumor regression revealing the potential of this approach. The study also reveals issues that need to be resolved including the design of vectors that provide high levels of persistent gene expression.
59. Stanislawski T., Voss R.H., Lotz C., Sadovnikova E., Willemsen R.A., Kuball J., Ruppert T., Bolhuis R.L., Melief C.J., Huber C., et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2 (2001) 962-970
60. Kershaw M.H., Teng M.W., Smyth M.J., and Darcy P.K. Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol 5 (2005) 928-940
61. Till B.G., Jensen M.C., Wang J., Chen E.Y., Wood B.L., Greisman H.A., Qian X., James S.E., Raubitschek A., Forman S.J., et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112 (2008) 2261-2271
62. Pule M.A., Savoldo B., Myers G.D., Rossig C., Russell H.V., Dotti G., Huls M.H., Liu E., Gee A.P., Mei Z., et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14 (2008) 1264-1270. This study demonstrates that EBV-specific T cells modified to express a chimeric antigen receptor that targets neuroblastoma have superior in vivo persistence and antitumor activity compared with non-virus-specific T cells modified with the same tumor-specific receptor after anti CD3 activation. These results are consistent with the EBV-specific T cells having the potential to persist as memory cells even when modified with a chimeric antigen receptor, although the frequency of persisting T cells was too low to determine their phenotype in vivo.